Paricalcitol
Based on 15 publication(s) in Google Scholar
Paricalcitol, a vitamin D analogue, is a vitamin D receptor agonist, used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.96%
- CAS 番号: 131918-61-1
- 分子式: C27H44O3
- 分子量:416.64
-
保管条件:
4°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Paricalcitol
More- Adv Sci (Weinh). 2024 Mar;11(10):e2305563. [Abstract]
- Cell Commun Signal. 2025 May 25;23(1):242. [Abstract]
- Biomed Pharmacother. 2020 May;125:109528. [Abstract]
- Antioxidants (Basel). 2023 Aug 18;12(8):1634. [Abstract]
- Int J Mol Sci. 2017 Dec 19;18(12). pii: E2764. [Abstract]
- Virol Sin. 2024 Aug 19:S1995-820X(24)00134-2. [Abstract]
- J Immunotoxicol. 2023 Dec;20(1):2248267. [Abstract]
- J Pharm Biomed Anal. 2020 Apr 15;182:113139. [Abstract]
- Endocrine. 2025 Aug;89(2):508-520. [Abstract]
- Am J Med Sci. 2016 Aug;352(2):208-14. [Abstract]
- Ir J Med Sci. 2018 Feb;187(1):75-84. [Abstract]
- J Nippon Med Sch. 2023;90(1):89-95. [Abstract]
- Turk J Biol. 2023 Mar 21;47(2):120-129. [Abstract]
- Oncotarget. 2017 Mar 28;8(13):21918-21929. [Abstract]
- Natl J Physiol Pharm Pharmacol. 2015;5(3).
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
RT-PCR
-
WB
-
IF
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HL-60 | EC50 |
12.5 nM
Compound: Paricalcitol
|
Induction of human HL60 cell differentiation after 4 days by NBT reduction assay
Induction of human HL60 cell differentiation after 4 days by NBT reduction assay
|
[PMID: 24035340] |
Paricalcitol (3×10-8 M; HP + PC) produces a significant reduction in calcification relative to the observed in cells in HP medium. Paricalcitol causes a reduction in the levels of nuclear β-catenin to a level similar to that observed in control cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 131918-61-1
-
性状 Solid
-
分子量 416.64
-
分子式 C27H44O3
-
Color White to off-white
-
SMILES
C[C@]([C@]([C@H](C)/C=C/[C@H](C)C(C)(C)O)([H])CC1)(CCC/2)[C@]1([H])C2=C\C=C3C[C@@H](O)C[C@H](O)C/3
-
別名
パリカルシトール
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (15)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
VDR Activation Attenuates Renal Tubular Epithelial Cell Ferroptosis by Regulating Nrf2/HO-1 Signaling Pathway in Diabetic Nephropathy. [Abstract]2024 Mar;11(10):e2305563. PMID: 38145959
Paricalcitol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Mar;11(10):e2305563. [Abstract]
VDR activation alleviated the injury of HK‐2 cells cultured in HG medium. Cell viability was quantified after the cells were cultured in different doses of Paricalcitol (PAR, 0-0.5 μM, 48 h) or Fer‐1 with 30 mm glucose medium for 48 h.
Paricalcitol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Mar;11(10):e2305563. [Abstract]
In the Fer-1 or Paricalcitol (PAR, 0.1 μM) treatment groups, the number of mitochondrial cristae increased, and reductions in mitochondrial volume were mitigated.2a stain Fer-1 or Paricalcitol (PAR, 0.1 μM) treatment apparently recovered the reduced GSH content induced by HG.
Paricalcitol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Mar;11(10):e2305563. [Abstract]
The qRT-PCR results showed that the mRNA expression levels of SLC7A11, GPX4, FTH1, and AIFM2 (the gene name for FSP1) were decreased in the HG group but reversed by Fer-1 or Paricalcitol (PAR, 0.1 μM) treatment. However, TFRC (the gene name for TFR-1) expression was completely reversed.
Paricalcitol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Mar;11(10):e2305563. [Abstract]
Western blotting analysis of different cell specimens with the respective densitometric measurements confirmed that the expression of ferroptosis-related proteins could be modulated by Fer-1 or Paricalcitol (PAR, 0.1 μM) treatment.
Paricalcitol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Mar;11(10):e2305563. [Abstract]
As corroborated by immunofluorescence analysis, SLC7A11 and GPX4 expression were increased, while TFR-1 expression was downregulated following treatment with Fer-1 or Paricalcitol (PAR).
Paricalcitol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Mar;11(10):e2305563. [Abstract]
VDR activation attenuated renal dysfunction in DN mice. The animal experiment was designed as shown in the schematic diagram. db/db mice aged 10 weeks were randomized to receive a daily i.p. injection of Fer-1 (5 mg/kg/day), Paricalcitol (PAR) (0.1 µg/kg/day) or an equal amount of vehicle for 10 weeks. Changes in the renal volume of mice in different groups at the endpoint.
Paricalcitol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Mar;11(10):e2305563. [Abstract]
In line with the in vitro western blotting findings, the expression levels of SLC7A11, GPX4, FTH-1 and FSP1 were enhanced in Fer-1- or Paricalcitol (PAR, 0.1 µg/kg/day)-treated mice, but TFR-1 expression was attenuated.
-
Cell Commun Signal
PRPF19 mediates the proteasomal degradation of VDR to exacerbate ferroptosis in diabetic nephropathy. [Abstract]2025 May 25;23(1):242. PMID: 40414879 -
Biomed Pharmacother
Paricalcitol improves experimental autoimmune encephalomyelitis (EAE) by suppressing inflammation via NF-κB signaling. [Abstract]2020 May;125:109528. PMID: 32106388 -
Antioxidants (Basel)
Fibroblast Upregulation of Vitamin D Receptor Represents a Self-Protective Response to Limit Fibroblast Proliferation and Activation during Pulmonary Fibrosis. [Abstract]2023 Aug 18;12(8):1634. PMID: 37627629 -
Int J Mol Sci
Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation. [Abstract]2017 Dec 19;18(12). pii: E2764. PMID: 29257109 -
Virol Sin
Antiviral activity of vitamin D derivatives against severe fever with thrombocytopenia syndrome virus in vitro and in vivo. [Abstract]2024 Aug 19:S1995-820X(24)00134-2. PMID: 39168248 -
J Immunotoxicol
Vitamin D/Vitamin D receptor mitigates cisplatin-induced acute kidney injury by down-regulating C5aR. [Abstract]2023 Dec;20(1):2248267. PMID: 37667858 -
J Pharm Biomed Anal
Active vitamin D and vitamin D analogs stimulate fibroblast growth factor 23 production in osteocyte-like cells via the vitamin D receptor. [Abstract]2020 Apr 15;182:113139. PMID: 32045827 -
Endocrine
A high-fat diet suppresses growth hormone synthesis and secretion by influencing the Vit D receptor and Pit1. [Abstract]2025 Aug;89(2):508-520. PMID: 40369297 -
Am J Med Sci
Effect of Combination of Angiotensin-Converting Enzyme Inhibitors and Vitamin D Receptor Activators on Cardiac Oxidative Stress in Diabetic Rats. [Abstract]2016 Aug;352(2):208-14. PMID: 27524220 -
Ir J Med Sci
Effect of paricalcitol on pancreatic oxidative stress, inflammatory markers, and glycemic status in diabetic rats. [Abstract]2018 Feb;187(1):75-84. PMID: 28551720 -
J Nippon Med Sch
Vitamin D Receptor Regulates Autophagy to Inhibit Apoptosis and Promote Proliferation in Hepatocyte Injury. [Abstract]2023;90(1):89-95. PMID: 36908130 -
Turk J Biol
Vitamin D receptor mediates liver ischemia and reperfusion injury by autophagy-regulated M2 macrophage polarization. [Abstract]2023 Mar 21;47(2):120-129. PMID: 37529163 -
Oncotarget
JMJD3 suppresses stem cell-like characteristics in breast cancer cells by downregulation of Oct4 independently of its demethylase activity. [Abstract]2017 Mar 28;8(13):21918-21929. PMID: 28423536
Paricalcitol purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Mar 28;8(13):21918-21929. [Abstract]
MDA-MB-231 cells were treated with 0, 1 or 10 nM Paricalcitol for 48 h. (A) mRNA expression of JMJD3 and UTX detected by RT-PCR. (B) Expression of JMJD3 and UTX detected by western blotting and the quantification results are presented on the right.
-
溶剤 & 溶解度
DMSO : 100 mg/mL (240.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 12.5 mg/mL (30.00 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
プロトコル
After TAC or sham surgery, a subset of the mice is treated with paricalcitol, a selective vitamin D receptor activator, which activates the VDR, at a final dose of 300 ng/kg/day. Paricalcitol is dissolved in a 95% propylene glycol and 5% ethyl alcohol solution. Mice are intraperitoneally injected with paricalcitol (or vehicle only) three times per week on Monday, Wednesday and Friday for five consecutive weeks. An established anti-hypertrophic and anti-fibrotic treatment, namely the angiotensin II receptor blocker (ARB) losartan is also included. Previous experiments have shown it is feasible and efficacious to dissolve losartan in the drinking water at a concentration of 30 mg/kg/day; mice are treated for five consecutive weeks. So, in total eight groups are studied. Sham (n=10), TAC (n=10), Sham + losartan (Sham-los, n=10), TAC + losartan (TAC-los, n=10), Sham + paricalcitol (Sham-pari, n=10), TAC + paricalcitol (TAC-pari, n=10), Sham + paricalcitol + losartan (Sham-combi, n=10) and TAC + paricalcitol + losartan (TAC-combi, n=10).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
純度とドキュメンテーション
-
データシート (276 KB)
-
SDS (604 KB)
- English - EN (604 KB)
- Français - FR (604 KB)
- Deutsch - DE (604 KB)
- Norwegian - NO (604 KB)
- Español - ES (604 KB)
- Swedish - SV (604 KB)
- Italian - IT (604 KB)
- Portuguese - PT (604 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Martinez-Moreno JM, et al. In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/beta-catenin activation. Am J Physiol Renal Physiol. 2012 Aug 8. [Content Brief]
[2]. Meems LM, et al. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol. 2012 Jul 16;132(3-5):282-289. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 2.4002 mL | 12.0008 mL | 24.0015 mL | 60.0038 mL |
| 5 mM | 0.4800 mL | 2.4002 mL | 4.8003 mL | 12.0008 mL | |
| 10 mM | 0.2400 mL | 1.2001 mL | 2.4002 mL | 6.0004 mL | |
| 15 mM | 0.1600 mL | 0.8001 mL | 1.6001 mL | 4.0003 mL | |
| 20 mM | 0.1200 mL | 0.6000 mL | 1.2001 mL | 3.0002 mL | |
| 25 mM | 0.0960 mL | 0.4800 mL | 0.9601 mL | 2.4002 mL | |
| DMSO | 40 mM | 0.0600 mL | 0.3000 mL | 0.6000 mL | 1.5001 mL |
| 50 mM | 0.0480 mL | 0.2400 mL | 0.4800 mL | 1.2001 mL | |
| 60 mM | 0.0400 mL | 0.2000 mL | 0.4000 mL | 1.0001 mL | |
| 80 mM | 0.0300 mL | 0.1500 mL | 0.3000 mL | 0.7500 mL | |
| 100 mM | 0.0240 mL | 0.1200 mL | 0.2400 mL | 0.6000 mL |
Powered by Bioz